Medtronic Plc (MDT) secured
FDA approval for the
Altaviva device, targeting urge urinary incontinence treatments. Medtronic is currently considered good value, indicating
Buy status by some analysts. It has been recommended for inclusion in dividend stock portfolios and displays strong institutional backing at 86%. The company announced the pricing of
€1.5 billion of Senior Notes and showed a 1.5% increase since the last earnings report. Expected to have a significant impact in the medical device market, MDT announced a
global study on a novel heart failure treatment, and another involving
cardiac pacing in new patient populations. Notably, it gained FDA approval for the
SmartGuard Algorithm as an Automated Glycemic Controller. The company's valuation remains in focus due to major board changes and strategic revamp, and strong
Q1 2026 earnings showed strong revenue growth, leading to an increased EPS guidance.
Medtronic Plc MDT News Analytics from Wed, 05 Feb 2025 08:00:00 GMT to Sat, 20 Sep 2025 16:46:02 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -3
